Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Geron Corporation (GERN : NSDQ)

• Company Description    Geron is a late-stage clinical biopharmaceutical company focused on the development and potential commercialization of a first-in-class telomerase inhibitor, imetelstat, in hematologic malignancies. The Company currently is conducting two Phase 3 clinical trials: IMerge in lower risk myelodysplastic syndromes and IMpactMF in refractory myelofibrosis. Number of Employees: 258

• Price / Volume Information    Yesterday's Closing Price: $1.42 Daily Weekly Monthly 20 Day Moving Average: 8,315,445 shares Shares Outstanding: 641.52 (millions) Market Capitalization: $910.96 (millions) Beta: 0.60 52 Week High: $2.01 52 Week Low: $1.04 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 7.58% 6.73% 12 Week -10.13% -12.33% Year To Date 7.58% -0.65%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 919 EAST HILLSDALE BOULEVARD SUITE 250 - FOSTER CITY,CA 94404 USA ph: 650-473-7700 fax: 650-473-7750 investor@geron.com http://www.geron.com

• General Corporate Information    Officers HAROUT SEMERJIAN - President; Chief Executive Officer ELIZABETH G. O'FARRELL - Chairman of the Board MICHELLE ROBERTSON - Executive Vice President; Finance; Chief Financial DAWN C. BIR - Director ROBERT J. SPIEGEL - Director Peer Information Geron Corporation (CORR.) Geron Corporation (RSPI) Geron Corporation (CGXP) Geron Corporation (BGEN) Geron Corporation (GTBP) Geron Corporation (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 374163103 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/26 Next Expected EPS Date: 08/05/26 Share - Related Items Shares Outstanding: 641.52 Most Recent Split Date: (:1) Beta: 0.60 Market Capitalization: $910.96 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $0.00 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.02 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/05/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 3.97 Price/Cash Flow: - Price / Sales: 4.65 EPS Growth vs. Year Ago Period: 66.67% vs. Previous Quarter: 66.67% Sales Growth vs. Year Ago Period: 30.89% vs. Previous Quarter: 7.96% ROE 06/30/26 - - 03/31/26 - -23.31 12/31/25 - -28.86 ROA 06/30/26 - - 03/31/26 - -10.08 12/31/25 - -12.83 Current Ratio 06/30/26 - - 03/31/26 - 6.78 12/31/25 - 4.66 Quick Ratio 06/30/26 - - 03/31/26 - 4.96 12/31/25 - 3.62 Operating Margin 06/30/26 - - 03/31/26 - -28.62 12/31/25 - -39.33 Net Margin 06/30/26 - - 03/31/26 - -35.48 12/31/25 - -46.65 Pre-Tax Margin 06/30/26 - - 03/31/26 - -34.32 12/31/25 - -45.41 Book Value 06/30/26 - - 03/31/26 - 0.36 12/31/25 - 0.35 Inventory Turnover 06/30/26 - - 03/31/26 - 0.05 12/31/25 - 0.06 Debt-to-Equity 06/30/26 - - 03/31/26 - 0.52 12/31/25 - 0.53 Debt-to-Capital 06/30/26 - - 03/31/26 - 34.34 12/31/25 - 34.61

Powered by Zacks Investment Research ©